News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

TetraLogic Pharmaceuticals Announces Presentation on Smac Mimetic Birinapant at American Society of Hematology Annual Meeting


12/10/2012 9:44:31 AM

MALVERN, Pa.--(BUSINESS WIRE)--TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule Smac mimetic drugs to treat cancer, today announced the poster presentation of preclinical data on its Smac mimetic drug candidate birinapant at the 54th ASH Annual Meeting and Exposition in Atlanta, Georgia. Birinapant has entered Phase 2 clinical trials for several solid tumors and a Phase 1/2 study in acute myeloid leukemia (AML) is ongoing.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES